| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 81 | NK 세포 활성을 통한 인플루엔자바이러스 감기 질환 예방과 면역 증강용 발효 조성물 | KR1020170067990 | 2017-05-31 | KR101853493B1 | 2018-04-30 | 남우식; 신동환; 이동석; 원병렬; 이희준; 남보라; 최유정; 김인철 |
| 본발명은 NK 세포활성을통한인플루엔자바이러스감기질환예방과면역증강용발효조성물에관한것으로, 탈지분유 3 중량부를기준으로, 50℃~60℃로가온된우유 70~85 중량부, 정제수 11~27 중량부를혼합하고, 혼합한후 90℃~100℃에서 25~35분간살균하고, 8℃~12℃로냉각한다음, 발효유산균 0.003~0.006 중량부,0.001~0.003 중량부0.001~0.003 중량부, 김치유래열처리유산균 0.01~0.04 중량부를접종하고, 접종한후 2시간동안 10℃에서 37℃로단계적으로상승시키며예비배양한다음, 37℃에서 5시간동안본 배양하고, 10℃로냉각하며, 상기발효유산균은이고, 상기김치유래열처리유산균은김치에서발생된인기술을제공함으로써 NK 세포활성을증진하는발효유산균이함유된조성물을이용하여다양한음용수또는식품등에첨가하여사람들이쉽게접하고, 섭취할수 있어인플루엔자바이러스감기질환예방할수 있는효과가있다. 또한, NK 세포의변화를통하여면역력이증진할뿐만아니라 EPS의함량이일반우유조성물보다 10배가량높아효소를활성시키는등의다양한효과를볼 수있고, 유산균의함량이높아기능성식품으로상품성이매우높아섭취자의건강을개선시킬수 있는효과도있다. | ||||||
| 82 | BIFIDOBACTERIA FOR TREATING CARDIAC CONDITIONS | US15744211 | 2016-07-07 | US20180200311A1 | 2018-07-19 | Lotta STENMAN; Sampo LAHTINEN; John KONHILAS |
| This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction, dilated cardiomyopathy, inflammatory heart disease (including endocarditis, inflammatory cardiomegaly and myocarditisl, and congestive heart failure. | ||||||
| 83 | SWEETENER COMPOSITIONS | US15687355 | 2017-08-25 | US20180070621A1 | 2018-03-15 | Dennis Wong; Horst Krupp |
| A sweetener composition comprising xylose, a sugar alcohol and brown seaweed extract in solid form, preferably powdered or crystalline form. The sugar alcohol is preferably an erythritol and the brown seaweed extract is preferably obtained from Laminaria japonica. The sweetener composition can further comprise one or a combination of additional vitamins, minerals, probiotic cultures, and other plant-based extracts. | ||||||
| 84 | USE OF COMPOSITIONS COMPRISING BIFIDOBACTERIUM ANIMALIS SSP. LACTIS LMG P-28149 | US15118077 | 2015-02-13 | US20160354418A1 | 2016-12-08 | Johan Quintens; Jehan Lienart van Lidth de Jeude; Corinne Grangette; Bruno Pot; Kassem Makki; Isabelle Wolowczuk; Jeanne Alard; Véronique Lehrter-Valenti |
| A composition made from at least one probiotic for the use of same in the curative treatment of body weight gain in an overweight human and/or in the preventive treatment of body weight gain in a human who is overweight or has been overweight, said probiotic being Bifidobacterium animalis ssp. Iactis n° LMG P-28149. | ||||||
| 85 | Use of Bifidobacterium Animalis for Treating or Preventing Body Weight Gain and Insulin Resistance | US14653546 | 2012-12-20 | US20150328266A1 | 2015-11-19 | Jian Shen; JingJing Wang; Liping Zhao; Martin Saul Obin; Muriel Derrien; Emilie Rocher; Johan Van Hylckama Vlieg |
| Provided is the use of Bifidobacterium animalis subsp. lactis strain CNCM I-2494 for decreasing diet-induced body weight gain and improving diet-induced insulin resistance in a subject. | ||||||
| 86 | Fermented food products containing probiotic strains, and their preparation process | US13706624 | 2012-12-06 | US09119415B2 | 2015-09-01 | Luc Terragno; Francois Debru; Philippe Teissier; Stephane Herve; Jean-Luc Blachon |
| The invention concerns mainly a non-solid fermented food product containing ferments comprising about 5·107, in particular more than about 108 bifidobacteria per gram of food product fermented for a shelf lifetime of at least 30 days, in particular of at least 35 days. | ||||||
| 87 | IMMUNOADJUVANT | US13878918 | 2011-10-14 | US20130195917A1 | 2013-08-01 | Dorte Eskesen |
| The invention thus relates to a method for boosting the efficiency of a vaccine by co-administering a probiotic bacterium such as L. casei 431 or BB-12 with an influenza vaccine. The invention further relates to a composition for use in such a treatment. | ||||||
| 88 | FERMENTED FOOD PRODUCTS CONTAINING PROBIOTIC STRAINS, AND THEIR PREPARATION PROCESS | US13706624 | 2012-12-06 | US20130095208A1 | 2013-04-18 | Luc TERRAGNO; Francois DEBRU; Philippe TEISSIER; Stephane HERVE; Jean-Luc BLACHON |
| The invention concerns mainly a non-solid fermented food product containing ferments comprising about 5·107, in particular more than about 108 bifidobacteria per gram of food product fermented for a shelf lifetime of at least 30 days, in particular of at least 35 days. | ||||||
| 89 | BIFIDOBACTERIA THAT PRODUCES FOLIC ACID, FOOD COMPOSITION AND USE OF SAID BIFIDOBACTERIA | US12993616 | 2009-05-21 | US20110268842A1 | 2011-11-03 | Elvira Garza Gonzalez; Francisco Javier Bosques Padilla; Sandra Naranjo Modad; Victor Manuel Moreno Campaña |
| A bacterial strain of human origin belonging to the species Bifidobacterium animalis identified as PTA-9175 which produces between 120 ng/ml to 398 ng/ml of folic acid and which can be used as a probiotic in food compositions. The Bifidobacterium animalis strain is deposited with the American Type Culture Collection (ATCC) in the United States of America, under the Budapest Treaty, dated on Apr. 23, 2008, and respectively identified with the ATCC deposit designation number for patent as PTA-9175. | ||||||
| 90 | Probiotic health or fitness promoting human or animal foodstuff and/or drinking water additive and use thereof | US11922136 | 2006-06-14 | US20100196323A1 | 2010-08-05 | Regina Plail; Gerd Schatzmayr; Eva Maria Binder; Michaela Mohnl; Alfred Klimitsch; Sabine Nitsch; Viviana Klose |
| The invention relates to a probiotic health or fitness promoting human or animal foodstuff and/or drinking water additive, comprising a mixture of microorganisms, selected from the group Enterococcus faecium, DSM 16211, Lactobacillus reuteri, DSM 16350, Lactobacillus salivarius ssp. salivarius, DSM 16351, Pediococcus acidilactici, DSM 16210, Bifidobacterium animalis and DSM 16284. The invention further relates to a use of the human or animal foodstuff and/or drinking water additive, in particular for prevention of the harmful effect of a number of undesirable germs in the digestive system of animals and/or domestic birds. | ||||||
| 91 | METHOD FOR STIMULATING INTESTINAL BARRIER INTEGRITY AFTER NON-NATURAL BIRTH | US12091047 | 2006-10-06 | US20090263537A1 | 2009-10-22 | Joachim Schmitt; Gunther Boehm |
| The present invention relates to methods for feeding and stimulating the health of infants delivered via caesarean section comprising administering long chain polyunsaturated fatty acids and/or nucleotides | ||||||
| 92 | FERMENTED FOOD PRODUCTS CONTAINING PROBIOTIC STRAINS AND METHOD FOR PREPARING SAME | US12013636 | 2008-01-14 | US20080175952A1 | 2008-07-24 | Luc TERRAGNO; Francois DEBRU; Philippe TEISSIER; Stephane HERVE; Jean-Luc BLACHON |
| The invention concerns mainly a non-solid fermented food product containing ferments comprising about 5·107, in particular more than about 108 bifidobacteria per gram of food product fermented for a shelf lifetime of at least 30 days, in particular of at least 35 days. | ||||||
| 93 | Strain of Bifidobacterium animalis ssp. animalis | US14651968 | 2013-12-10 | US10064902B2 | 2018-09-04 | Sophie Legrain-Raspaud; Gianfranco Grompone; Sandrine Capronnier; Tamara Smokvina; Marie-Christine Degivry; Biliana Lesic; Michel Neunlist |
| The invention relates to a novel strain of Bifidobacterium animals ssp. animalis, which is able, inter alia, to improve the function of the enteric nervous system, and to compositions said novel strain. | ||||||
| 94 | COMPOSITION FOR REDUCING INTESTINAL GAS PRODUCTION | US15568014 | 2015-04-23 | US20180133266A1 | 2018-05-17 | Boris LE NEVE; Émilie ROCHER; Denis GUYONNET |
| The present invention relates to a composition comprising Bifidobacterium bacteria for use for reducing intestinal gas production in an individual. | ||||||
| 95 | Method for stimulating the intestinal flora | US14973166 | 2015-12-17 | US09596876B2 | 2017-03-21 | Günther Boehm; Bernd Stahl; Jan Knol |
| The present invention relates to methods for feeding and to compositions to be administered to infants delivered via caesarian section and in particular to the use of a) at least two different microorganisms; or b) at least one microorganism and at least one indigestible oligosaccharide; or c)at least two different Bifidobacteria species, subspecies or strains for the manufacture of a composition for enteral administration to an infant delivered via caesarean section. Thereby it is possible to stimulate the healthy development of the intestinal flora of said infants. | ||||||
| 96 | Preventing diseases in infants delivered via caesarean section | US14813845 | 2015-07-30 | US09585416B2 | 2017-03-07 | Joachim Schmitt; Bernd Stahl; Jan Knol |
| The present invention provides the use of a composition comprising non-digestible oligosaccharide for the manufacture of a composition for enteral administration to an infant delivered via caesarean section. | ||||||
| 97 | COMPOSITION WITH SYNBIOTICS | US15080913 | 2016-03-25 | US20160338397A1 | 2016-11-24 | Jan KNOL; Bernd STAHL |
| Nutritional compositions with health benefits comprising bacterial strains and galactooligosaccharides are disclosed. | ||||||
| 98 | NOVEL COMPOSITIONS | US15092473 | 2016-04-06 | US20160235105A1 | 2016-08-18 | BIRGITTE YDE; Jakob Blenker SVENDSEN |
| The invention relates to a dry compositions for lactic acid bacteria and in particular to a dry composition comprising from 109 to 1013 cfu/g of the composition of lactic acid bacteria cells, wherein the composition is characterized by that it also comprises following amounts of protective agents (all amounts of protective agents below are given relative to 1 g of lactic acid bacteria cells in the composition): from 6 to 9 g of trehalose, from 0.1 to 1 g of inulin and from 0.5 to 3 g of hydrolyzed casein, and by that it does not comprise a salt of alginic acid. The composition has an improved storage stability of the cell of interest. Comparison experiments have been made between compositions with and without alginate and it has been found that there is substantially no difference between compositions with or without alginate with regard to stability. Further, the invention relates to a method for preparing a dry lactic acid bacteria composition. | ||||||
| 99 | PREVENTING DISEASES IN INFANTS DELIVERED VIA CAESAREAN SECTION | US14813845 | 2015-07-30 | US20150335053A1 | 2015-11-26 | Joachim SCHMITT; Bernd STAHL; Jan KNOL |
| The present invention provides the use of a composition comprising non-digestible oligosaccharide for the manufacture of a composition for enteral administration to an infant delivered via caesarean section. | ||||||
| 100 | STRAIN OF BIFIDOBACTERIUM ANIMALIS SSP. ANIMALIS | US14651968 | 2013-12-10 | US20150320807A1 | 2015-11-12 | Sophie LEGRAIN-RASPAUD; Gianfranco GROMPONE; Sandrine CAPRONNIER; Tamara SMOKVINA; Marie-Christine DEGIVRY; Biliana LESIC; Michel NEUNLIST |
| The invention relates to a novel strain of Bifidobacterium animals ssp. animalis, which is able, inter alia, to improve the function of the enteric nervous system, and to compositions said novel strain. | ||||||
QQ群二维码
意见反馈
意见反馈